AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.5900
-0.1800 (-3.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.7700
Open4.7600
Bid4.5900 x 1400
Ask4.6000 x 1300
Day's Range4.4821 - 4.8000
52 Week Range2.3400 - 7.5200
Volume1,586,833
Avg. Volume1,962,961
Market Cap578.996M
Beta (3Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-3.8180
Earnings DateOct 31, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est6.40
Trade prices are not sourced from all markets
  • All You Need to Know About Akorn (AKRX) Rating Upgrade to Buy
    Zacks

    All You Need to Know About Akorn (AKRX) Rating Upgrade to Buy

    Akorn (AKRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Benzinga

    The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...

  • GlobeNewswire

    Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

    LAKE FOREST, Ill., Oct. 14, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire

    Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, October 31, 2019 outlining its third quarter 2019 financial results. In addition, the Company has scheduled a conference call at 10:00 a.m. ET on the same day to discuss its third quarter 2019 financial and operating results. To access the live webcast, please go to Akorn’s Investor Relations website at http://investors.akorn.com.

  • Should You Be Concerned About Akorn, Inc.'s (NASDAQ:AKRX) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Akorn, Inc.'s (NASDAQ:AKRX) Historical Volatility?

    If you own shares in Akorn, Inc. (NASDAQ:AKRX) then it's worth thinking about how it contributes to the volatility of...

  • GlobeNewswire

    Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%

    LAKE FOREST, Ill., Aug. 26, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • Is Akorn (NASDAQ:AKRX) A Risky Investment?
    Simply Wall St.

    Is Akorn (NASDAQ:AKRX) A Risky Investment?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Thomson Reuters StreetEvents

    Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT

    Q2 2019 Akorn Inc Earnings Call

  • Akorn (AKRX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Akorn (AKRX) Q2 2019 Earnings Call Transcript

    AKRX earnings call for the period ending June 30, 2019.

  • Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates

    Akorn (AKRX) delivered earnings and revenue surprises of 66.67% and 3.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for

    Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its second quarter 2019 financial results. In addition, the Company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss its second quarter 2019 financial results. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

  • Markit

    See what the IHS Markit Score report has to say about Akorn Inc.

    Akorn Inc NASDAQ/NGS:AKRXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AKRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 5. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $62.66 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire

    Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. According to IQVIA, U.S. sales of Loteprednol Etabonate Ophthalmic Suspension, 0.5% were approximately $90 million for the twelve months ended April 2019.

  • Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • Benzinga

    Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

    Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug Administration related to the inspection of its Somerset, New Jersey manufacturing facility in July and August 2018. Akorn said it is committed to the highest standards of quality and compliance and will continue to work collaboratively with the FDA to resolve issues addressed in the warning letter.

  • Reuters

    Akorn gets FDA warning letter for another manufacturing plant

    The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.

  • Akorn Files Complaint on Fresenius' Canceled Bid
    Investopedia

    Akorn Files Complaint on Fresenius' Canceled Bid

    Akorn said it will 'vigorously' protest Fresenius' plans to drop its planned $4.75B acquisition.

  • TheStreet.com

    Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility

    said Tuesday that it received a warning letter from the U.S. Food & Drug Administration regarding an inspection of the company's Somerset, New Jersey facility in July and August 2018. The Lake Forest, Illinois-based company said in a statement that it will respond to the FDA letter within the required 15 working days. "Akorn is committed to resolving the warning letter in a comprehensive and effective manner," Douglas Boothe, president and CEO, said in the statement.

  • Reuters

    UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

    Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker. The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.

  • GlobeNewswire

    Akorn Receives FDA Warning Letter

    Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter.  The Company will respond to the FDA letter within the required 15 working days from receipt of the letter. Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “Akorn is committed to resolving the warning letter in a comprehensive and effective manner.

  • How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GlobeNewswire

    Akorn to Present at the Jefferies 2019 Global Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at http://investors.akorn.com/events-and-presentations. The webcast may include forward-looking statements about, among other things, the Company’s business plans and initiatives, the Company’s commitments to the FDA and remediation efforts, disruptions during the Standstill Period, the Company’s anticipated future operating and financial performance, business plans and prospects, product pipeline, including filings, approvals and launches, capital allocation, debt refinancing, and potential dispositions, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.